JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Design, Classification, and Therapeutic Applications of Prodrugs in Modern Drug Development

Naveena Vasavi Sri Durga P*[1], Govinda Rao Kamala[2]

[1] *UG Scholar, Department of Pharmaceutical Chemistry, Koringa College of Pharmacy, Korangi, Kakinada, Andhra Pradesh, India*
[2] *Professor and Vice Principal, Department of Pharmaceutical Chemistry, Koringa College of Pharmacy, Korangi, Kakinada, Andhra Pradesh, India*

Publication history: Received on 14th May 2025; Revised on 10th June 2025; Accepted on 20th June 2025

Article DOI: 10.69613/2mqr8d80

Abstract: Prodrugs represent chemically modified inactive derivatives of active drug molecules that undergo biotransformation to release the parent drug upon administration. The field of prodrug development has evolved significantly over the past decades, offering solutions to various pharmaceutical and pharmacokinetic limitations of existing drugs. The concept originated in 1958 has grown into a sophisticated drug design approach, addressing challenges like poor solubility, limited bioavailability, inadequate tissue targeting, and undesirable side effects. Recent developments in prodrug design have led to enhanced oral bioavailability and tumor-specific targeting through various mechanisms including enzyme-activated systems, carrier-linked modifications, and site-specific delivery approaches. Modern prodrug strategies incorporate advanced delivery systems such as antibody-directed enzyme prodrug therapy (ADEPT) and gene-directed enzyme prodrug therapy (GDEPT), enabling precise drug targeting and activation. Membrane transporters, particularly peptide transporters like PEPT1 and PEPT2, play crucial roles in prodrug absorption and distribution. The success of prodrugs in clinical applications is evident from various approved medications, including antiviral agents like sofosbuvir and baloxavir marboxil, demonstrating improved pharmacokinetic profiles and therapeutic outcomes. Recent advances in photodynamic therapy and enzyme-activated prodrugs have opened new avenues in cancer treatment, while carrier-linked and mutual prodrugs offer innovative solutions for various therapeutic challenges.

Keywords: Bioactivation; Drug Delivery Systems; Enzyme-Activated Prodrugs; Pharmacokinetics; Site-Specific Targeting

1. Introduction

The concept of prodrugs emerged as a revolutionary approach in pharmaceutical development, marking a significant advancement in drug delivery systems. First introduced in 1958 by Albert, prodrugs are pharmacologically inactive compounds that undergo biotransformation *in vivo* to release the active drug moiety [1]. This innovative strategy has evolved from simple chemical modifications to sophisticated drug delivery systems addressing multiple therapeutic challenges [2]. The fundamental principle underlying prodrug design involves the temporary modification of drug molecules through biorevocible derivatization, fundamentally altering their physicochemical properties while preserving their therapeutic potential [3]. These modifications can enhance various parameters including solubility, permeability, stability, and site-specific delivery, ultimately improving the drug's therapeutic index [4].

The rationale for prodrug development stems from various pharmaceutical and pharmacokinetic limitations encountered in drug development. Poor aqueous solubility, inadequate membrane permeability, limited oral bioavailability, and undesirable side effects often hinder the successful development of potentially valuable therapeutic agents [5]. Additionally, the challenge of targeted drug delivery, particularly in cancer therapy, has driven significant innovations in prodrug design [6]. Recent advances in prodrug technology have led to remarkable improvements in drug targeting and delivery systems. The development of tumor-activated prodrugs, for instance, has revolutionized cancer therapy by enabling site-specific drug activation [7]. The emergence of sophisticated delivery strategies such as antibody-directed enzyme prodrug therapy (ADEPT) and gene-directed enzyme prodrug therapy (GDEPT) has further expanded the therapeutic potential of prodrugs [8].

In the pharmaceutical industry, approximately 10% of all marketed medications worldwide can be classified as prodrugs, with a higher percentage among drugs approved in recent years [9]. This increasing trend reflects the growing recognition of prodrug strategies as valuable tools in drug development. The success of prodrugs like capecitabine in cancer therapy and enalapril in cardiovascular treatment demonstrates their clinical significance [10].

* Corresponding author: Naveena Vasavi Sri Durga P

The evolution of prodrug design has been paralleled by advances in understanding cellular transport mechanisms, enzymatic processes, and tissue-specific activation pathways [11]. These insights have enabled the development of more sophisticated prodrug strategies, including membrane transporter-targeted prodrugs and enzyme-specific activation systems [12]. Modern prodrug development encompasses various approaches, from simple chemical modifications to complex targeted delivery systems. The selection of appropriate prodrug strategies depends on multiple factors, including the physicochemical properties of the parent drug, the desired therapeutic outcome, and the specific biological barriers to be overcome [13].



Figure 1. Prodrug Development Process

2. Classification of Prodrugs

2.1. Carrier-Linked Prodrugs

Carrier-linked prodrugs represent a major category where the active drug is temporarily linked to a carrier molecule through a bioreversible covalent bond [14]. The carrier moiety is selected based on its ability to alter specific physicochemical properties while ensuring efficient release of the parent drug *in vivo* [15].

Table 1. Classification and Examples of Major Prodrug Categories

Category	Mechanism	Examples	Therapeutic Area	Advantage Achieved
Carrier-Linked Prodrugs	Ester hydrolysis	Enalapril	Cardiovascular	Enhanced oral bioavailability
	Amide cleavage	Olmesartan medoxomil	Hypertension	Improved absorption
	Phosphate cleavage	Sofosbuvir	Antiviral	Better cellular uptake
	Carbonate hydrolysis	Capecitabine	Oncology	Tumor-specific activation
Bioprecursor Prodrugs	Oxidation	Minoxidil	Hair growth	Targeted activation
	Reduction	Sulindac	Anti-inflammatory	Improved activity
Site-Specific Prodrugs	Enzyme activation	Irinotecan	Oncology	Reduced toxicity
	pH-dependent	Doxorubicin-HPMA	Oncology	Enhanced targeting
Mutual Prodrugs	Co-drug formation	Sulfasalazine	Anti-inflammatory	Synergistic effects

2.1.1. Simple Carrier-Linked Prodrugs

These prodrugs contain a single carrier molecule attached to the active drug through specific functional groups such as esters, amides, carbonates, or phosphates [16]. The selection of the linkage depends on various factors including:

2.1.2. Ester Prodrugs

Ester formation represents the most common approach in prodrug design, accounting for approximately 49% of all marketed prodrugs [17]. These prodrugs undergo hydrolysis by esterases present in blood, liver, and other tissues. Examples include oseltamivir phosphate, which exhibits enhanced oral bioavailability compared to its parent compound [18].

2.1.3. Amide Prodrugs

Amide bonds, though more stable than esters, offer advantages in specific situations where slower drug release is desired [19]. The activation of amide prodrugs typically involves peptidases or amidases, as demonstrated by the antihypertensive drug olmesartan medoxomil [20].

2.2. Double Prodrugs

Also known as pro-prodrugs or cascade-latentiated prodrugs, these systems require two distinct biotransformation steps to release the active drug [21]. The first step converts the initial prodrug to an intermediate prodrug, which subsequently undergoes a second transformation to release the active molecule. This approach offers enhanced control over drug release and targeting [22].

2.3. Bioprecursor Prodrugs

Bioprecursor prodrugs undergo molecular modification through metabolic biotransformation to generate the active drug [23]. Unlike carrier-linked prodrugs, they do not involve the release of a carrier molecule.

2.3.1. Metabolic Oxidation/Reduction Based Prodrugs

These prodrugs utilize oxidative or reductive metabolic processes for activation. For example, the anti-inflammatory agent sulindac undergoes reduction of its sulfoxide group to form the active metabolite [24].

2.3.2. Metabolic Cyclization Based Prodrugs

Such prodrugs undergo intramolecular cyclization following an initial enzymatic reaction. The ACE inhibitor enalapril exemplifies this category, where cyclization occurs following ester hydrolysis [25].



Figure 2. Mechanisms Involved in Prodrug Activation

2.4. Site-Specific Prodrugs

2.4.1. Tissue-Specific Prodrugs

Tissue-specific prodrugs are strategically designed to target specific tissues or organs by exploiting their unique physiological or metabolic characteristics [26]. The design principles incorporate several critical factors for targeted drug delivery. Tissue-specific enzyme expression patterns serve as a primary basis for selective drug activation in target tissues. Local pH variations across different physiological compartments enable pH-dependent drug release mechanisms. The presence of specific membrane transporters in target tissues facilitates selective drug uptake and accumulation. Additionally, unique physiological conditions characteristic of specific tissues or disease states can trigger prodrug activation in desired locations.

2.4.2. Tumor-Specific Prodrugs

Tumor-specific prodrugs leverage the distinctive characteristics of tumor tissues for selective activation [27]. The hypoxic environment commonly found in solid tumors enables the development of hypoxia-activated prodrugs, which undergo selective

activation in oxygen-depleted tumor regions. Enzyme-activated prodrugs utilize elevated levels of specific enzymes frequently overexpressed in tumor tissues. pH-sensitive prodrugs take advantage of the acidic microenvironment typically associated with tumor tissues, enabling selective drug release under these specific conditions.

2.5. Mutual Prodrugs

Mutual prodrugs represent an innovative approach where two pharmacologically active compounds are chemically coupled, with each molecule serving as a carrier for the other [28]. This strategic combination enhances therapeutic effects through complementary or synergistic mechanisms of action. The mutual prodrug approach effectively reduces side effects by modifying the release characteristics of both active compounds. Drug targeting improves through the combined physicochemical properties of the coupled molecules. The synergistic effects achieved through this approach often result in enhanced therapeutic outcomes compared to individual drug administration. This design technique has proven particularly valuable in developing treatments for complex diseases requiring multi-targeted therapeutic applications.

3. Prodrug Design and Mechanisms

3.1. Chemical Linker Techniques

The selection of appropriate chemical linkers represents a fundamental aspect of prodrug design, determining both the stability and activation characteristics of the final molecule [29]. Chemical linkers must maintain stability during storage and initial drug administration while enabling efficient release of the parent drug at the target site.

Table 2. Common Chemical Linkages Used in Prodrug Design

Linkage Type	Stability (pH 7.4)	Main Activation Mechanism	Applications
Ester	Hours to days	Esterases	Oral delivery
Amide	Days to weeks	Peptidases	Sustained release
Phosphate	Variable	Phosphatases	Water solubility
Carbamate	Weeks	Esterases/Chemical	Sustained release
Carbonate	Days	Esterases	Lipophilicity
Imine	Minutes to hours	pH-dependent	Targeting

3.1.1. Ester-Based Linkers

Ester linkages remain the most extensively utilized in prodrug development owing to their versatile nature and predictable hydrolysis patterns. These linkers exhibit varying half-lives, ranging from minutes to several hours, depending on their chemical structure and surrounding molecular environment [30]. For instance, the camptothecin derivative EBZ-2208 demonstrates a plasma half-life of 12.3 minutes, while IT-101 exhibits extended stability with a half-life of approximately 1.7 hours, illustrating the significant impact of molecular design on hydrolysis rates [31].

3.1.2. Amide and Carbamate Linkers

Amide and carbamate linkages provide enhanced stability compared to ester bonds, making them suitable for applications requiring prolonged circulation times or specific enzymatic activation [32]. These linkers often demonstrate resistance to plasma esterases while maintaining susceptibility to target-specific enzymes.

3.2. Targeting Ligand Conjugation

3.2.1. Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) represent a sophisticated approach in targeted prodrug delivery, utilizing the high specificity of monoclonal antibodies for tumor-associated antigens [33]. The optimization of drug-to-antibody ratio proves crucial for maximizing therapeutic efficacy while maintaining acceptable pharmacokinetic properties. Current ADC development focuses on enhancing tissue penetration and reducing immunogenicity [34].

3.2.2. Peptide-Drug Conjugates

Peptide-based targeting offers advantages over antibody conjugates due to their smaller molecular size, superior tissue penetration, and reduced immunogenic potential [35]. These conjugates can be designed to target specific peptide transporters or receptors overexpressed in cancer cells, enabling selective drug delivery.

3.2.3. Aptamer-Drug Conjugates

Aptamer conjugation represents an emerging strategy in prodrug design, offering advantages of chemical synthesis scalability and reduced batch-to-batch variation compared to protein-based targeting approaches [36]. These synthetic oligonucleotide-based carriers demonstrate high target specificity while maintaining favorable pharmacokinetic properties.

3.3. Enzyme-Activated Systems

3.3.1. Endogenous Enzyme Activation

Prodrugs designed for activation by endogenous enzymes exploit differential enzyme expression patterns between target and non-target tissues [37]. This approach has proven particularly effective in cancer therapy, where tumor-specific enzyme expression enables selective drug activation.

3.3.2. ADEPT and GDEPT Systems

Antibody-directed enzyme prodrug therapy (ADEPT) and gene-directed enzyme prodrug therapy (GDEPT) represent advanced strategies for site-specific prodrug activation [38]. These systems involve the localized delivery of activating enzymes through antibody conjugation or gene transfer, followed by administration of enzyme-specific prodrugs.

3.4. Membrane Transporter-Mediated Delivery

The exploitation of membrane transporters, particularly peptide transporters like PEPT1 and PEPT2, has emerged as a powerful strategy for enhancing prodrug absorption and distribution [39]. These systems enable the targeted delivery of prodrugs to specific tissues expressing relevant transporters, improving therapeutic efficiency and reducing systemic exposure.



Figure 3: Carrier-Linked Prodrug Design

4. Therapeutic Applications of Prodrugs

4.1. Cancer Therapy

4.1.1. Photodynamic Therapy

Photodynamic therapy (PDT) utilizing prodrug approaches has emerged as a significant advancement in cancer treatment, offering selective tumor destruction with minimal damage to surrounding healthy tissues [40]. The development of 5-aminolevulinic acid (ALA) and its derivatives represents a major breakthrough in PDT. ALA serves as an endogenous prodrug in the heme biosynthetic pathway, leading to selective accumulation of protoporphyrin IX in cancer cells [41]. Recent modifications of ALA, including dendritic derivatives and glycosidated compounds, have demonstrated enhanced cellular uptake and improved therapeutic outcomes [42].

4.1.2. Enzyme-Activated Anticancer Prodrugs

The development of enzyme-activated prodrugs has revolutionized targeted cancer therapy through two primary approaches: ADEPT and GDEPT. These systems achieve higher therapeutic indices through localized drug activation [43]. The ADEPT system employs tumor-specific antibodies conjugated to activating enzymes, enabling selective conversion of subsequently administered prodrugs at tumor sites. This approach has demonstrated particular success in treating solid tumors resistant to conventional chemotherapy [44].

Table 3. Parameters in Prodrug Development

Parameter	Consideration	Critical Range/Value	Impact
Aqueous Solubility	> 0.1 mg/mL	0.1-1.0 mg/mL	Bioavailability
Lipophilicity (logP)	0-5	1.5-3.0	Membrane permeability
Chemical Stability	t½ > 2 years	pH 1-8	Shelf life
Enzymatic Stability	Variable	Species dependent	Drug release
Molecular Weight	< 1000 Da	400-700 Da	Absorption

4.1.3. Iron Chelator Prodrugs

Iron chelator prodrugs represent an innovative approach in cancer therapy, targeting the crucial role of iron in tumor cell proliferation. Modern prochelator designs incorporate sophisticated activation mechanisms responsive to the tumor microenvironment, such as elevated hydrogen peroxide levels [45]. These systems effectively regulate iron availability while minimizing interference with normal iron homeostasis in healthy tissues.

4.2. Cardiovascular Drugs

4.2.1. Antihypertensive Prodrugs

Prodrug approaches in cardiovascular medicine have significantly improved the therapeutic profiles of various antihypertensive agents. ACE inhibitor prodrugs, such as enalapril and ramipril, demonstrate enhanced oral bioavailability and prolonged duration of action compared to their active counterparts [46]. The ester prodrug strategy employed in these medications enables efficient absorption and subsequent enzymatic activation to their active forms.

4.2.2. Anticoagulant Prodrugs

Modern anticoagulant therapy has benefited substantially from prodrug development. Dabigatran etexilate represents a successful example, offering improved oral absorption through strategic esterification of the parent compound [47]. The prodrug design overcomes the poor bioavailability of the active molecule while maintaining its potent anticoagulant effects.

4.3. Antiviral Therapy

4.3.1. Nucleoside Analog Prodrugs

The development of nucleoside analog prodrugs has transformed antiviral therapy, particularly in treating HIV and hepatitis infections. The ProTide technology, incorporating phosphoramidate modifications, has led to significant improvements in drug delivery and efficacy [48]. Sofosbuvir, a prominent example, demonstrates enhanced liver targeting and improved antiviral activity against hepatitis C virus through its prodrug design [49].

4.3.2. Influenza Therapeutics

Recent advances in influenza treatment include the development of baloxavir marboxil, a prodrug targeting viral cap-dependent endonuclease. This approach offers advantages over traditional neuraminidase inhibitors through a novel mechanism of action and improved pharmacokinetic properties [50].

4.4. Central Nervous System Disorders

4.4.1. Blood-Brain Barrier Penetration

Prodrug strategies have successfully addressed the challenge of blood-brain barrier penetration in CNS drug delivery. Lipophilic prodrug modifications enhance brain uptake of otherwise poorly penetrating therapeutic agents [51]. This approach has proven particularly valuable in treating neurological disorders and brain tumors.

4.4.2. Neurodegenerative Disease Treatment

In treating neurodegenerative conditions, prodrug approaches have improved the delivery and efficacy of various therapeutic agents. The development of enzyme-specific prodrugs targeting neural tissues has enabled more selective drug distribution and reduced systemic side effects [52].

Table 4. Therapeutic Advantages and Limitations of Different Prodrug Techniques

Approach	Advantages	Major Limitations
Ester Prodrugs	Well-understood	Limited targeting
ADCs	High specificity	Manufacturing complexity
ADEPT	Selective activation	Immunogenicity
Bioprecursor	Simple design	Variable metabolism
Targeted Prodrugs	Reduced side effects	Complex development

5. Conclusion

Prodrugs are a dynamic and continually evolving area of pharmaceutical research that has fundamentally transformed drug delivery approaches. Through decades of innovation and technological advancement, prodrug strategies have successfully addressed numerous challenges in drug development, including poor solubility, limited bioavailability, and inadequate target specificity. The success of prodrug approaches is evidenced by the increasing number of approved prodrugs in clinical use, with approximately 10% of all marketed drugs now utilizing prodrug technology. This trend shows the pharmaceutical industry's growing recognition of prodrug strategies as valuable tools in overcoming drug delivery challenges. The versatility of prodrug design, from simple chemical modifications to sophisticated targeted delivery systems, has enabled remarkable improvements in therapeutic outcomes across various disease states. The advent of novel technologies such as antibody-drug conjugates, smart delivery systems, and tissue-specific activation mechanisms represents significant progress in achieving selective drug targeting. These developments have particularly impacted cancer therapy, where targeted prodrug approaches have demonstrated superior therapeutic indices compared to conventional treatments. However, several challenges remain in prodrug development, including the need for more precise control over drug release kinetics, better activation mechanisms, and better prediction of *in vivo* behavior. The complexity of biological systems and individual patient variability continues to present challenges in prodrug design and optimization.

References

[1] Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Järvinen T, et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov. 2008;7(3):255-70.

[2] Huttunen KM, Raunio H, Rautio J. Prodrugs—from serendipity to rational design. Pharmacol Rev. 2011;63(3):750-71.

[3] Stella VJ, Nti-Addae KW. Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev. 2007;59(7):677-94.

[4] Wu KM. A new classification of prodrugs: regulatory perspectives. Pharmaceuticals. 2009;2(3):77-81.

[5] Jana S, Mandlekar S, Marathe P. Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists. Curr Med Chem. 2010;17(32):3874-908.

[6] Denny WA. Tumor-activated prodrugs—a new approach to cancer therapy. Cancer Invest. 2004;22(4):604-19.

[7] Singh Y, Palombo M, Sinko PJ. Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem. 2008;15(18):1802-26.

[8] Rooseboom M, Commandeur JN, Vermeulen NP. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev. 2004;56(1):53-102.

[9] Rautio J, Meanwell NA, Di L, Hageman MJ. The expanding role of prodrugs in contemporary drug design and development. Nat Rev Drug Discov. 2018;17(8):559-87.

[10] Zawilska JB, Wojcieszak J, Olejniczak AB. Prodrugs: a challenge for the drug development. Pharmacol Rep. 2013;65(1):1-14.

[11] Stella VJ. Prodrugs: Some thoughts and current issues. J Pharm Sci. 2010;99(12):4755-65.

[12] Han HK, Amidon GL. Targeted prodrug design to optimize drug delivery. AAPS PharmSci. 2000;2(1):48-58.

[13] Mahato R, Tai W, Cheng K. Prodrugs for improving tumor targetability and efficiency. Adv Drug Deliv Rev. 2011;63(8):659-70.

[14] Testa B. Prodrug research: futile or fertile? Biochem Pharmacol. 2004;68(11):2097-106.

[15] Ettmayer P, Amidon GL, Clement B, Testa B. Lessons learned from marketed and investigational prodrugs. J Med Chem. 2004;47(10):2393-404.

[16] Yang Y, Aloysius H, Inoyama D, Chen Y, Hu L. Enzyme-mediated hydrolytic activation of prodrugs. Acta Pharm Sin B. 2011;1(3):143-59.

[17] Beaumont K, Webster R, Gardner I, Dack K. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr Drug Metab. 2003;4(6):461-85.

[18] Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of *in vitro* drug product dissolution and *in vivo* bioavailability. Pharm Res. 1995;12(3):413-20.

[19] Simplício AL, Clancy JM, Gilmer JF. Prodrugs for amines. Molecules. 2008;13(3):519-47.

[20] Mizuno M, Minami K, Yamazaki M, Takano M, Takei S. Olmesartan medoxomil: high-performance liquid chromatographic determination in human plasma and application to a pharmacokinetic study. Biomed Chromatogr. 2005;19(9):677-83.

[21] Zhang Y, Sun J, Sun Y, Wang Y, He Z. Prodrug design targeting intestinal PepT1 for improved oral absorption: design and performance. Curr Drug Metab. 2013;14(6):675-87.

[22] Stella VJ, Charman WN, Naringrekar VH. Prodrugs: Do they have advantages in clinical practice? Drugs. 1985;29(5):455-73.

[23] Huttunen KM, Rautio J. Prodrugs - an efficient way to breach delivery and targeting barriers. Curr Top Med Chem. 2011;11(18):2265-87.

[24] Duggan DE, Hooke KF, Hwang SS. Kinetics of the tissue distributions of sulindac and metabolites. Drug Metab Dispos. 1980;8(4):241-6.

[25] Todd PA, Heel RC. Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs. 1986;31(3):198-248.

[26] Bodor N, Buchwald P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv Drug Deliv Rev. 1999;36(2-3):229-54.

[27] Denny WA, Wilson WR. Tumor-activated prodrugs - a new approach to cancer therapy. Cancer Metastasis Rev. 1993;12(2):135-51.

[28] Das N, Dhanawat M, Dash B, Nagarwal RC, Shrivastava SK. Codrug: an efficient approach for drug optimization. Eur J Pharm Sci. 2010;41(5):571-88.

[29] Kratz F, Müller IA, Ryppa C, Warnecke A. Prodrug strategies in anticancer chemotherapy. ChemMedChem. 2008;3(1):20-53.

[30] Taylor MD. Improved passive oral drug delivery via prodrugs. Adv Drug Deliv Rev. 1996;19(2):131-48

[31] Cheng J, Khin KT, Jensen GS, Liu A, Davis ME. Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjug Chem. 2003;14(5):1007-17.

[32] Svenson S, Tomalia DA. Dendrimers in biomedical applications--reflections on the field. Adv Drug Deliv Rev. 2005;57(15):2106-29.

[33] Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15-29.

[34] Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-37.

[35] Gao W, Chan JM, Farokhzad OC. pH-Responsive nanoparticles for drug delivery. Mol Pharm. 2010;7(6):1913-20.

[36] Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov. 2010;9(7):537-50.

[37] Denny WA. Prodrug strategies in cancer therapy. Eur J Med Chem. 2001;36(7-8):577-95.

[38] Niculescu-Duvaz I, Springer CJ. Antibody-directed enzyme prodrug therapy (ADEPT): a review. Adv Drug Deliv Rev. 1997;26(2-3):151-72.

[39] Brandsch M, Knütter I, Bosse-Doenecke E. Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol. 2008;60(5):543-85.

[40] Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011;61(4):250-81.

[41] Peng Q, Berg K, Moan J, Kongshaug M, Nesland JM. 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol. 1997;65(2):235-51.

[42] Fotinos N, Campo MA, Popowycz F, Gurny R, Lange N. 5-Aminolevulinic acid derivatives in photomedicine: Characteristics, application and perspectives. Photochem Photobiol. 2006;82(4):994-1015.

[43] Sharma SK, Bagshawe KD, Melton RG, Sherwood RF. Antibody directed enzyme prodrug therapy (ADEPT): trials and tribulations. Adv Drug Deliv Rev. 1996;22(3):247-64.

[44] Bagshawe KD. Antibody directed enzymes revive anti-cancer prodrugs concept. Br J Cancer. 1987;56(5):531-2.

[45] Richardson DR, Kalinowski DS, Lau S, Jansson PJ, Lovejoy DB. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta. 2009;1790(7):702-17.

[46] Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97(14):1411-20.

[47] van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116-27.

[48] Mehellou Y, Balzarini J, McGuigan C. Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells. ChemMedChem. 2009;4(11):1779-91.

[49] Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, et al. Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 2010;53(19):7202-18.

[50] Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379(10):913-23.

[51] Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3-14.

[52] Anderson BD. Prodrugs for improved CNS delivery. Adv Drug Deliv Rev. 1996;19(2):171-202.